DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings

Simply Wall St

Sun, February 15, 2026 at 9:36 PM GMT+9 3 min read

In this article:

DMAC
-1.16%

Over the last year, a good number of insiders have significantly increased their holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC). This is encouraging because it indicates that insiders are more optimistic about the company’s prospects.

Although we don’t think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At DiaMedica Therapeutics

In the last twelve months, the biggest single purchase by an insider was when insider Thomas von Koch bought US$10.0m worth of shares at a price of US$3.50 per share. Even though the purchase was made at a significantly lower price than the recent price (US$8.53), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn’t tell us much about what they think of current prices.

DiaMedica Therapeutics insiders may have bought shares in the last year, but they didn’t sell any. The average buy price was around US$4.40. We don’t deny that it is nice to see insiders buying stock in the company. But we must note that the investments were made at well below today’s share price. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for DiaMedica Therapeutics

NasdaqCM:DMAC Insider Trading Volume February 15th 2026

DiaMedica Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

DiaMedica Therapeutics Insiders Bought Stock Recently

It’s good to see that DiaMedica Therapeutics insiders have made notable investments in the company’s shares. Specifically, insider Jan Stahlberg bought US$15m worth of shares in that time, and we didn’t record any sales whatsoever. This is a positive in our book as it implies some confidence.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It’s great to see that DiaMedica Therapeutics insiders own 47% of the company, worth about US$216m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

Story Continues

So What Does This Data Suggest About DiaMedica Therapeutics Insiders?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn’t make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about DiaMedica Therapeutics. That’s what I like to see! So while it’s helpful to know what insiders are doing in terms of buying or selling, it’s also helpful to know the risks that a particular company is facing. Our analysis shows 4 warning signs for DiaMedica Therapeutics (2 don’t sit too well with us!) and we strongly recommend you look at these before investing.

If you would prefer to check out another company – one with potentially superior financials – then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch** with us directly.**_ Alternatively, email editorial-team (at) simplywallst.com._

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Terms and Privacy Policy

Privacy Dashboard

More Info